Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial

Araki, Eiichi; Yamashita, Shizuya; Arai, Hidenori; Yokote, Koutaro; Satoh, Jo; Inoguchi, Toyoshi; Nakamura, Jiro; Maegawa, Hiroshi; Yoshioka, Narihito; Tanizawa, Yukio; Watada, Hirotaka; Suganami, Hideki; Ishibashi, Shun

doi:10.2337/dc17-1589

Public

Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial

Published in Diabetes Care • Jan 3, 2018

Authors:

Eiichi Araki

Shizuya Yamashita

Hidenori Arai

Abstract

OBJECTIVE Type 2 diabetes is frequently complicated with atherogenic dyslipidemia. This study aimed to evaluate the efficacy and safety of pemafibrate (K-877) in patients with type 2 diabetes comorbid with hypertriglyceridemia. RESEARCH DESIGN AND METHODS Patients were randomly assigned to three gro...

Subject

Hypertriglyceridemia

Internal medicine

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!